Cargando…
Bone-Targeted Agents for the Management of Breast Cancer Patients with Bone Metastases
Despite advances in adjuvant therapy for breast cancer, bone remains the most common site of recurrence. The goal of therapy for these patients is palliative and focused on maximizing the duration and quality of their life, while concurrently minimizing any disease or treatment-related complications...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470229/ https://www.ncbi.nlm.nih.gov/pubmed/26237063 http://dx.doi.org/10.3390/jcm2030067 |
_version_ | 1782376734045241344 |
---|---|
author | Simos, Demetrios Addison, Christina L. Kuchuk, Iryna Hutton, Brian Mazzarello, Sasha Clemons, Mark |
author_facet | Simos, Demetrios Addison, Christina L. Kuchuk, Iryna Hutton, Brian Mazzarello, Sasha Clemons, Mark |
author_sort | Simos, Demetrios |
collection | PubMed |
description | Despite advances in adjuvant therapy for breast cancer, bone remains the most common site of recurrence. The goal of therapy for these patients is palliative and focused on maximizing the duration and quality of their life, while concurrently minimizing any disease or treatment-related complications. Bone metastases predispose patients to reduced survival, pain, impaired quality of life and the development of skeletal-related events. With an increased understanding of the pathophysiology of bone metastasis, effective treatments for their management have evolved and are now in widespread clinical use. This article will discuss the pathogenesis of bone metastases and review the key clinical evidence for the efficacy and safety of currently available systemic bone-targeted therapies in breast cancer patients with an emphasis on bisphosphonates and the receptor activator of nuclear factor kappa B ligand (RANKL) inhibitors. We will also discuss novel strategies and therapies currently in development. |
format | Online Article Text |
id | pubmed-4470229 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-44702292015-07-28 Bone-Targeted Agents for the Management of Breast Cancer Patients with Bone Metastases Simos, Demetrios Addison, Christina L. Kuchuk, Iryna Hutton, Brian Mazzarello, Sasha Clemons, Mark J Clin Med Review Despite advances in adjuvant therapy for breast cancer, bone remains the most common site of recurrence. The goal of therapy for these patients is palliative and focused on maximizing the duration and quality of their life, while concurrently minimizing any disease or treatment-related complications. Bone metastases predispose patients to reduced survival, pain, impaired quality of life and the development of skeletal-related events. With an increased understanding of the pathophysiology of bone metastasis, effective treatments for their management have evolved and are now in widespread clinical use. This article will discuss the pathogenesis of bone metastases and review the key clinical evidence for the efficacy and safety of currently available systemic bone-targeted therapies in breast cancer patients with an emphasis on bisphosphonates and the receptor activator of nuclear factor kappa B ligand (RANKL) inhibitors. We will also discuss novel strategies and therapies currently in development. MDPI 2013-08-19 /pmc/articles/PMC4470229/ /pubmed/26237063 http://dx.doi.org/10.3390/jcm2030067 Text en © 2013 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0/ This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). |
spellingShingle | Review Simos, Demetrios Addison, Christina L. Kuchuk, Iryna Hutton, Brian Mazzarello, Sasha Clemons, Mark Bone-Targeted Agents for the Management of Breast Cancer Patients with Bone Metastases |
title | Bone-Targeted Agents for the Management of Breast Cancer Patients with Bone Metastases |
title_full | Bone-Targeted Agents for the Management of Breast Cancer Patients with Bone Metastases |
title_fullStr | Bone-Targeted Agents for the Management of Breast Cancer Patients with Bone Metastases |
title_full_unstemmed | Bone-Targeted Agents for the Management of Breast Cancer Patients with Bone Metastases |
title_short | Bone-Targeted Agents for the Management of Breast Cancer Patients with Bone Metastases |
title_sort | bone-targeted agents for the management of breast cancer patients with bone metastases |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470229/ https://www.ncbi.nlm.nih.gov/pubmed/26237063 http://dx.doi.org/10.3390/jcm2030067 |
work_keys_str_mv | AT simosdemetrios bonetargetedagentsforthemanagementofbreastcancerpatientswithbonemetastases AT addisonchristinal bonetargetedagentsforthemanagementofbreastcancerpatientswithbonemetastases AT kuchukiryna bonetargetedagentsforthemanagementofbreastcancerpatientswithbonemetastases AT huttonbrian bonetargetedagentsforthemanagementofbreastcancerpatientswithbonemetastases AT mazzarellosasha bonetargetedagentsforthemanagementofbreastcancerpatientswithbonemetastases AT clemonsmark bonetargetedagentsforthemanagementofbreastcancerpatientswithbonemetastases |